Search Results
Your search for ,foR matches 32722 pages
Showing 31301 - 31350No Survival Benefit of Video-Assisted Thoracoscopic Partial Pleurectomy vs Talc Pleurodesis in Malignant Pleural Mesothelioma
In light of nonrandomized studies suggesting benefit of video-assisted thoracoscopic partial pleurectomy (VAT-PP) in symptom control and survival, Rintoul et al performed a randomized trial (MesoVATS) of VAT-PP vs talc pleurodesis in malignant pleural mesothelioma. As reported in The Lancet, this...
No Increased Risk for Cancer in Patients Receiving Tumor Necrosis Factor–Alpha Antagonists for Inflammatory Bowel Disease
Some data indicate an increased risk for cancer in patients receiving tumor necrosis factor (TNF)-alpha antagonists (eg, infliximab [Remicade], adalimumab [Humira], certolizumab pegol [Cimzia]) for rheumatoid arthritis. Studies with follow-up of ≤ 1 year have not found increased risk in patients ...
FDA Approves Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to belinostat (Beleodaq), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin lymphoma (NHL). “This is...
Propensity-Matched Analysis Shows Similar Outcomes for Segmentectomy vs Lobectomy in Stage I NSCLC
Recent retrospective, single-institution analyses have suggested that anatomic segmentectomy results in freedom from recurrence and survival rates similar to those achieved by lobectomy in lung cancer. In a large propensity-matched analysis reported in the Journal of Clinical Oncology, Landreneau...
Study Identifies Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
In a systematic review and meta-analysis reported in the Journal of the National Cancer Institute, Friebel et al attempted to identify factors that appear to modulate risk of breast and ovarian cancer in women who have inherited BRCA1 or BRCA2 mutations. Although the ability to perform...
No Improvement in Local Recurrence With Brachytherapy After Sublobar Resection in Patients With High-Risk Stage I NSCLC
In the phase III American College of Surgeons Oncology Group (ACOSOG) Z4032/Alliance trial reported in the Journal of Clinical Oncology, Fernando et al found that adjuvant brachytherapy did not improve risk for local recurrence after sublobar resection in patients with high-risk stage I operable...
Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones
A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...
Abbreviated Screening MRI Protocol Is Highly Accurate in Breast Cancer Detection in Women at Increased Risk
As reported in the Journal of Clinical Oncology, Kuhl et al assessed whether an abbreviated breast magnetic resonance imaging (MRI) protocol, consisting of one pre- and one postcontrast acquisition and derived images—first postcontrast–subtracted (FAST) and maximum-intensity...
Study Shows Annual MRI Plus Mammography May Be Effective Screening Program for Women at High Risk for Breast Cancer
The Ontario Breast Screening Program expanded in July 2011 to include screening of high-risk women aged 30 to 69 years with annual magnetic resonance imaging (MRI) and digital mammography. As reported by Chiarelli et al in Journal of Clinical Oncology, a study of the initial screen in the program...
Multifaceted Intervention Improves Adherence to Annual Colorectal Cancer Screening in Primarily Latino Community Health Centers
Colorectal cancer screening rates are low among Latinos and people living in poverty. In a study reported in JAMA Internal Medicine, Baker et al found that a multifaceted intervention more than doubled adherence to screening with fecal occult blood testing in a largely Latino and uninsured...
5-Year Results of the European EXPERT-C Trial Show Benefit of Cetuximab in TP53 Wild-Type Rectal Cancer Subgroup
In an updated analysis of the European phase II EXPERT-C trial reported in the Journal of the National Cancer Institute, Sclafani et al found that adding cetuximab (Erbitux) to neoadjuvant capecitabine plus oxaliplatin (CAPOX) followed by chemoradiotherapy, surgery, and adjuvant CAPOX produced no...
HIV-Infected People With Early-Stage Cancers Are Up to Four Times More Likely to Go Untreated for Cancer
HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a large retrospective study from researchers in Penn Medicine’s Abramson Cancer Center and the National Cancer Institute (NCI). The ...
Adding Rilotumumab to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Hepatocyte growth factor (HGF) and its receptor MET have been found to promote the proliferation, migration, and survival of tumor cells and to play a role in gastric cancer. In a phase II study reported in The Lancet Oncology, Iveson et al found evidence of benefit from adding the anti-HGF...
FDA Grants Breakthrough Therapy Designation to Blinatumomab for Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to blinatumomab for adults with Philadelphia chromosome–negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow....
Postdiagnosis Calcium and Milk Intake May Be Associated With Improved Overall Survival in Colorectal Cancer Patients
Higher intakes of calcium, vitamin D, and dairy product are associated with lower risk of colorectal cancer, but the effect of such intake on survival in colorectal cancer is unclear. In a study reported in the Journal of Clinical Oncology, Yang et al found that higher postdiagnosis intake of...
Excess Risk of Chronic Late Effects of Treatment in Children With Standard-Risk ALL
Given the changes in treatment of children with acute lymphoblastic leukemia (ALL), the risk of late effects in those treated with current protocols may be different from that in children treated decades ago. In a study of survivors of childhood standard-risk ALL reported in The Lancet Oncology,...
Surgical Treatment for Metastatic Melanoma of the Liver Increases Overall Survival in Select Group of Patients
Surgical resection markedly improved survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the Journal of the American College of Surgeons. These results mark a departure for melanoma, which is most often...
New Screening Approach Identifies Cancer Mutations in Melanoma That May Lead to More Effective Immunotherapies
Although cancer immunotherapy with adoptive transfer of tumor-infiltrating lymphocytes represents an effective treatment for patients with metastatic melanoma, the antigen targets recognized by these effective tumor-infiltrating lymphocytes remain unclear. According to a new study, a novel...
Phase III Trial Shows Improved Survival With TAS-102 in Metastatic Colorectal Cancer Refractory to Standard Therapies
The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract O-0022). “Around 50%...
Telephone-Based Intervention Produces Weight Loss in Postmenopausal Women With Breast Cancer Receiving Letrozole
Obesity is associated with poorer outcome in women with operable breast cancer. In the LISA study reported in the Journal of Clinical Oncology, Goodwin et al found that a 24-month telephone-based intervention was effective in reducing body weight in postmenopausal breast cancer patients receiving...
American College of Physicians Issues Guideline Recommending Against Routine Pelvic Exams for Asymptomatic Women
A new evidence-based clinical practice guideline from the American College of Physicians (ACP) is recommending that physicians should not offer routine pelvic examinations to asymptomatic, average-risk, nonpregnant women. The recommendation stems from a review of 52 published articles from 1946...
Phase II Trial Shows Improved Progression-Free Survival but Greater Toxicity With Selumetinib vs Chemotherapy in Metastatic Uveal Melanoma
Oncogenic mutations in GNAQ and GNA11, resulting in MAPK pathway activation, are observed in > 80% of uveal melanomas. In a phase II trial reported in JAMA, Carvajal et al found that treatment with the MEK1/MEK2 inhibitor selumetinib significantly prolonged progression-free survival vs...
Study of Over 450,000 Women Finds 3D Mammography Detects More Invasive Cancers and Reduces Recall Rates
Researchers found that three-dimensional (3D) mammography (also known as digital breast tomosynthesis) detected significantly more invasive cancers than a traditional mammogram alone and reduced call-backs for additional imaging. Published in JAMA, this is the largest study reported to...
Immediate Breast Reconstruction After Mastectomy More Likely Among Canadian Women With Higher Income Who Are Treated at Teaching Hospitals
In a study reported in the Journal of Clinical Oncology, Zhong et al assessed factors associated with use of immediate breast reconstruction after treatment or prophylaxis for breast cancer among women in the Canadian universal health-care system. Immediate breast reconstruction was more likely in...
No Benefit of Adding Telomerase Peptide Vaccine to Chemotherapy in Patients With Advanced Pancreatic Cancer
In a UK phase III TeloVac trial reported in The Lancet Oncology, Middleton et al found that the sequential or concurrent addition of the telomerase peptide vaccine GV1001 to gemcitabine/capecitabine did not improve survival in patients with locally advanced or metastatic pancreatic cancer. GV1001...
Uninsured Young Adults Have Poorer Cancer-Specific Outcomes
The Patient Protection and Affordable Care Act is likely to improve insurance coverage for young adults. In a study reported in the Journal of Clinical Oncology, Aizer et al examined the association between insurance status and cancer outcomes among young adults, finding that the uninsured...
HPV-Positive Disease Predicts Longer Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
Patients with human papillomavirus (HPV)-positive oropharyngeal cancer have reduced risk of progression compared with those with HPV-negative disease, but the effect of HPV status on overall survival after progression has not been clear. In a study reported in the Journal of Clinical Oncology,...
Adding Novel Agent to Standard Therapy Improves Survival in Patients With Pancreatic Cancer After Prior Gemcitabine-Based Therapy
The addition of the novel agent MM-398 to standard treatment improved overall survival in patients with metastatic pancreatic cancer who have already received gemcitabine, according to a phase III trial reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract...
FDA Advisory Committee Votes Against Accelerated Approval for Olaparib in Ovarian Cancer
The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have...
No Disease-Free Survival Benefit of Adding Cetuximab to FOLFOX4 in KRAS Exon 2 Wild-Type Resected Stage III Colon Cancer
In an interim analysis of the European phase III PETACC-8 trial reported in The Lancet Oncology, Taieb et al found no disease-free survival or overall survival benefit with the addition of cetuximab (Erbitux) to standard adjuvant FOLFOX4 (oxaliplatin, fluorouracil, leucovorin) therapy in patients...
St. Jude Children’s Research Hospital Appoints James R. Downing, MD, as CEO
St. Jude Children’s Research Hospital announced the appointment of James R. Downing, MD, as its new CEO, effective July 15, 2014. Dr. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital. He succeeds William E. Evans,...
High Neutrophil-to-Lymphocyte Ratio Is Associated With Poorer Survival in Solid Tumors Overall and in Individual Cancer Types
In a systematic review and meta-analysis reported in Journal of the National Cancer Institute, Templeton et al found that high neutrophil-to-lymphocyte ratio, a marker of inflammation, is associated with significantly poorer overall survival in solid tumors overall and by individual category. High...
Synthetic Triterpenoids Show Promise in Preventing Colitis-Associated Colon Cancer in Preclinical Study
Researchers from Case Western Reserve and Dartmouth have shown that a class of small antioxidant molecules carries promise for suppressing colon cancer associated with colitis. These preclinical findings, published in the Journal of Clinical Investigation, offer hope that physicians ultimately will ...
Event-Free Survival Benefit, Greater Toxicity of Augmented Postremission Therapy for Children/Young Adults With High-Risk Acute Lymphoblastic Leukemia
In a UK phase III trial (UKALL 2003) reported in The Lancet Oncology, Vora et al found that augmented postremission therapy provided an event-free survival benefit at the cost of increased toxicity in children and young adults with clinical standard- or intermediate-risk but minimal residual...
Phase III Trial Indicates That S-1 Monotherapy Should Remain Standard Treatment of Locally Advanced Gastric Cancer in Japan
The oral fluoropyrimidine S-1 is standard treatment for locally advanced gastric cancer in Japan. In a Japanese phase III trial (SAMIT) in locally advanced disease reported in The Lancet Oncology, Tsuburaya et al found that sequential paclitaxel plus tegafur and uracil or S-1 did not improve...
Daily Low-Dose Aspirin Use May Reduce Risk of Developing Pancreatic Cancer
Men and women who took low-dose aspirin regularly had a 48% reduction in their risk of developing pancreatic cancer, according to a new study. In addition, the longer a person started taking low-dose aspirin, the greater the benefit, ranging from 48% reduction in people who started 3 years before...
No Overall Survival Improvement but Some Palliative Benefit With Gefitinib vs Placebo in Esophageal Cancer Progressing After Chemotherapy
In what may be the first randomized trial of systemic therapy in this setting, Dutton and colleagues evaluated gefitinib (Iressa) vs placebo in patients with esophageal cancer progressing after chemotherapy. As reported in The Lancet Oncology, the COG trial showed no survival benefit with gefitinib ...
BPA Stimulates Growth of Breast Cancer Cells, Diminishes Effect of Treatment
Bisphenol A (BPA), a chemical commonly used in plastics, appears to increase the proliferation of breast cancer cells, according to Duke Medicine researchers presenting at ICE/ENDO 2014, the annual joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago. The ...
Oncologist Communication Skills Training Program Effective for Both Oncologists and Patients
In a Japanese study reported in the Journal of Clinical Oncology, Fujimori et al found that an oncologist communication skills training program based on patient preferences in receiving bad news was of benefit to both oncologists and patients. Study Details In the study, 30 oncologists were...
Tumor Microenvironment of Metastasis Score Independently Predicts Distant Metastasis in Estrogen Receptor–Positive/HER2-Negative Breast Cancer
Tumor microenvironment of metastasis (TMEM) consists of direct contact between a macrophage, an endothelial cell, and a tumor cell. In a case-control study reported in the Journal of the National Cancer Institute, Rohan et al found that TMEM score was an independent predictor of distant metastasis...
Adding Antiangiopoietin Agent Trebananib to Paclitaxel Improves Progression-Free Survival in Recurrent Epithelial Ovarian Cancer
Trebananib inhibits angiogenesis by blocking the binding of angiopoietins 1 and 2 to the Tie2 receptor expressed on endothelial cells, a mechanism that differs from VEGF inhibitors and that involves a different signaling pathway. In the phase III TRINOVA-1 trial reported in The Lancet Oncology,...
Combining Multiple Imaging Approaches Can Better Distinguish Malignant and Benign Breast Tumors and Reduce Unnecessary Biopsies
A new study found that an imaging technique called multiparametric 18fluorodeoxyglucose positron-emission tomography magnetic resonance imaging (18FDG PET-MRI), which combines four imaging approaches, can better distinguish malignant breast tumors from those that are benign, compared with imaging...
Early Evidence Suggests Proton Therapy May Offer Safe, Long-Term Treatment for Hodgkin Lymphoma
Despite some success in treating patients with Hodgkin lymphoma, many patients may experience late effects of radiation therapy and chemotherapy treatment, including the possible onset of breast cancer or heart disease. A study by Hoppe et al from the University of Florida Proton Therapy Institute...
New Tool Predicts Financial Pain for Cancer Patients
In an online report in the journal Cancer, a team of University of Chicago cancer specialists have described the first tool—11 questions, assembled and refined from conversations with more than 150 patients with advanced cancer—to measure a patient’s risk for, and ability to...
No Improvement in Long-Term Outcomes With Extended Colectomy for Sporadic Colorectal Cancer in Patients Younger Than Age 50
Extended colectomy in patients with sporadic colorectal cancer who were younger than age 50, in comparison with segmental resection, did not improve the risk of tumor recurrence or disease-free survival, according to the results of a retrospective study presented by Klos et al in the Journal of...
HERA Trial 8-Year Follow-up Shows Low Rate of Trastuzumab-Associated Cardiac Dysfunction
In a study reported in Journal of Clinical Oncology, Azambuja et al found low rates of trastuzumab (Herceptin)-related cardiac dysfunction over a median of 8 years of follow-up in the HERceptin Adjuvant (HERA) trial. The majority of patients with cardiac dysfunction achieved acute recovery. Study...
EPIC Cohort Study: High Thyroglobulin and Low TSH Precede Differentiated Thyroid Cancer, but Neither Can Be Used in Screening
In a study of the association of thyroid-stimulating hormone (TSH), thyroglobulin, and thyroid hormones with risk of differentiated thyroid cancer reported in Journal of the National Cancer Institute, Rinaldi et al found that high thyroglobulin levels can precede thyroid cancer by many years and...
Development of Orteronel for Prostate Cancer Voluntarily Discontinued by Takeda
Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700), an investigational oral, nonsteroidal, selective inhibitor of 17,20-lyase, for prostate cancer. The decision follows the results of two phase III...
Racial Disparities in Sentinel Lymph Node Biopsy in Women With Breast Cancer
A study by Black et al from The University of Texas MD Anderson Cancer Center, Houston, found that the use of sentinel lymph node biopsy to stage early breast cancer increased in both black and white women from 2002 to 2007, but the rates remained lower in black than white patients, a disparity...
Diversity of Intestinal Tract Bacteria Associated With Mortality Outcomes After Stem Cell Transplant, Study Shows
New research published online in Blood suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. Potential Connections Previous studies have shown that the intensive treatment...
